Tooba A. Cheema

Oncor (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index1.3kcitations42works1.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(25), Herpesvirus Infections and Treatments(16), CAR-T cell therapy research(10), RNA Interference and Gene Delivery(8), Viral Infectious Diseases and Gene Expression in Insects(7)

Publications42 total

Author Correction: Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy
Nature Cancer·2026Open Access
Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy
Nature Cancer·2025· 3 cited
Supplementary Figure 1 from Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts
2023Open Access
Supplementary Figure 1 from Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts
2023Open Access
Supplementary Figure Legend from Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts
2023Open Access
Data from Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts
2023Open Access
Supplementary Figure Legend from Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts
2023Open Access
Data from Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts
2023Open Access
Supplementary Figure Legends 1-6 from Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication
2023Open Access
Supplementary Figures 1-6 from Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication
2023Open Access
Supplementary Materials and Methods from Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication
2023Open Access
Supplementary Materials and Methods from Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication
2023Open Access
Supplementary Figure Legends 1-6 from Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication
2023Open Access
Supplementary Figures 1-6 from Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication
2023Open Access
Data from Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication
2023Open Access
Data from Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication
2023Open Access
511 Initial results of a phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors
Regular and Young Investigator Award Abstracts·2021· 9 citedOpen Access
Abstract OT2-07-06: Antibody-coupled T cell receptor (ACTR) engineered autologous T cells in combination with trastuzumab for the treatment of HER2-positive malignancies
Cancer Research·2019
Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
Nature Medicine·2019· 11 citedOpen Access
A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
Blood·2018· 6 cited
page 1 of 3Next →

Frequent Co-authors

Samuel D. Rabkin(22), Robert L. Martuza(21), Hiroaki Wakimoto(20), Brent J. Passer(17), Bingsen Zhou(9), Cécile Zaupa(9), Mani Razmjoo(9), Jason Sarte(9), Chin‐Lee Wu(9), James W. Noah(9), Qianjun Li(9), John K. Buolamwini(9), Yun Yen(9), Ryuichi Kanai(8), Geon Woo Kim(7), Stephen K. Fisher(5), Peter E. Fecci(4), Ryan Boomer(4), Seth A. Ettenberg(4), Shulin Wu(4)